Pfizer to Acquire Medivation (Enzalutamide) for $14 B

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Pfizer to Acquire Medivation (Enzalutamide) for $14 B

posted on Aug 22, 2016 08:32AM

Medivation, the company who created Xtandi (Enzalutamide) along with Astellas, has been purchased by Pfizer for $14B. Recall that Zenith will be testing a combination therapy of ZEN-3694 together with Enzalutamide in its mCRPC trial.

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply